This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Certara, Inc. (CERT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Certara (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -1.92% and 8.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical (PROF) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Profound Medical (PROF) delivered earnings and revenue surprises of -24.14% and 24.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.43% and 9.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 9.48% and 5.93%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -17.24% and 20.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
60 Degrees Pharmaceuticals Inc. (SXTP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
60 Degrees Pharmaceuticals Inc. (SXTP) delivered earnings and revenue surprises of -55% and 60%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
ElectroCore, Inc. (ECOR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
electroCore (ECOR) delivered earnings and revenue surprises of -6.90% and 1.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Journey Medical (DERM) delivered earnings and revenue surprises of 29.41% and 1.87%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 28.19% and 3.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -16.67% and 3.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -33.90% and 20.83%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Enanta Pharmaceuticals (ENTA): Can Its 13.8% Jump Turn into More Strength?
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The Zacks Analyst Blog Highlights Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World
by Zacks Equity Research
Enanta, OneConnect Financial, KNOT Offshore, Hippo Holdings and H World are included in this Analyst Blog.
5 Secret Santa Stocks to Pop Surprise Returns
by Sweta Killa
Enanta Pharmaceuticals (ENTA), OneConnect Financial. (OCFT), KNOT Offshore (KNOP), Hippo Holdings (HIPO) and H World Group (HTHT) could surprise investors with big returns this Christmas.
Wall Street Analysts Predict a 108.12% Upside in Enanta Pharmaceuticals (ENTA): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 108.1% in Enanta Pharmaceuticals (ENTA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Enanta Pharmaceuticals (ENTA)? Wall Street Analysts Think 88.23%
by Zacks Equity Research
The mean of analysts' price targets for Enanta Pharmaceuticals (ENTA) points to an 88.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Analysts Estimate Enanta Pharmaceuticals (ENTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alpine Immune Sciences, Inc. (ALPN) Surges 8.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.